Author

Maher Abdel-Sattar

Observed names: Abdel-Sattar, Maher, M. Abdel-Sattar, M. Abdel‐Sattar

Institution: Indivior (United States)

Observed institutions: University of California, San Francisco, Indivior (United States)

ORCID: 0009-0002-1942-6477

Observed ORCID: 0009-0002-1942-6477

OpenAlex ID: A5005036418

Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States

2015 · Jie Ting, PharmD Tien Ho, et al. · Value in Health · 68

The relationship between risk of bias criteria, research outcomes, and study sponsorship in a cohort of preclinical thiazolidinedione animal studies: a meta‐analysis

2014 · M. Abdel‐Sattar, D. Krauth, et al. · Evidence-based Preclinical Medicine · 14

The Food and Drug Administration reports provided more data but were more difficult to use than the European Medicines Agency reports

2014 · Jeppe Bennekou Schroll, Maher Abdel-Sattar, et al. · Journal of Clinical Epidemiology · 10

Association between extended-release buprenorphine adherence and reduced healthcare costs among insured patients with opioid use disorder

2026 · Michelle Jerry, Divya Venkat, et al. · Frontiers in Public Health · 5

Relationship between extended-release buprenorphine adherence and reduced risk of return to use in patients with opioid use disorder: A retrospective claims data analysis

2026 · Michelle Jerry, Divya Venkat, et al. · Drug and Alcohol Dependence Reports · 1

Cost-Effectiveness of Afatinib, Erlotinib, and Cisplatin/Pemetrexed for First-Line Treatment of Metastatic Egfr-Mutation Positive Non-Small Cell Lung Cancer

2014 · J. Ting, T. Ho, et al. · Value in Health · 1

Impact of opioid agonist therapies on non-fatal and fatal overdose: treatment patterns among individuals with opioid use disorder in Ontario, Canada

2026 · Kenneth Lee, Vincent Lam, et al. · Frontiers in Public Health

Works count: 9

Citation count: 100

H-index: 4

I10-index: 3